Lisa P. Spees

Lisa P. Spees

Auto-generated profile, based on publicly available information

Lisa P. Spees

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Gynecologic Oncology
Verified
Journal Article
Closed access
LSLisa P. Spees
Lisa P. Spees
SWStephanie B. Wheeler
Stephanie B. Wheeler
MVMahesh Varia
Mahesh Varia
MWMorris Weinberger
Morris Weinberger
CBChristopher D. Baggett
Christopher D. Baggett
WBWendy R. Brewster
Wendy R. Brewster

1 May 2019 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
LSLisa P. Spees
Lisa P. Spees
WBWendy R. Brewster
Wendy R. Brewster
MVMahesh A. Varia
Mahesh A. Varia
MWMorris Weinberger
Morris Weinberger
CBChristopher Baggett
Christopher Baggett
SWStephanie B. Wheeler
Stephanie B. Wheeler
Background: Although rural cancer patients encounter substantial barriers to care, they more often report receiving timely care than urban patients. We examined whether geographic distance, a contributor to urban–rural health disparities, differentially influences treatment initiation and completion among insured urban and rural cervical cancer patients. Methods: We identified women diagnosed with cervical cancer from 2004 to 2013 from a statewide cancer registry linked to multipayer, insurance claims. Primary outcomes were initiation of guideline-concordant care within 6 weeks of diagnosis and, among stage IB2-IVA cancer patients, completion of concurrent chemoradiotherapy (CCRT) in 56 days. We estimated risk ratios using modified Poisson regressions, stratified by urban/rural status, to examine the association between distance and treatment timing (initiation or completion). Results: Among 999 stage IA-IVA patients, 48% initiated guideline-concordant care within 6 weeks of diagnosis, and 37% of 492 stage IB2-IVA cancer patients completed CCRT in 56 days. In urban areas, stage IA-IVA patients who lived ≥15 miles from the nearest treatment facility were less likely to initiate timely treatment compared with those <5 miles [risk ratio (RR): 0.72; 95% confidence intervals (CI), 0.54–0.95]. Among IB2-IVA stage cancer patients, rural women residing ≥15 miles from the nearest radiation facility were more likely to complete CCRT in 56 days (RR: 2.49; 95% CI, 1.12–5.51). Conclusions: Geographic distance differentially influences the initiation and completion of treatment among urban and rural cervical cancer patients. Impact: Distance was an access barrier for insured cervical cancer patients in urban areas whereas rural patients may require more intensive outreach, support, and resources, even among those living closer to treatment.

2 September 2024 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
APArrianna Marie Marie Planey
Arrianna Marie Marie Planey
LSLisa P Spees
Lisa P Spees
CBCaitlin B Biddell
Caitlin B Biddell
AWAustin Waters
Austin Waters
EJEmily P. Jones
Emily P. Jones
SWStephanie B Wheeler
Stephanie B Wheeler
Background: In addition to greater delays in cancer screening and greater financial hardship, rural-dwelling cancer patients experience greater costs associated with accessing cancer care, including higher cumulative travel costs. This study aimed to identify and synthesize peer-reviewed research on the cumulative and overlapping costs associated with care access and utilization. Methods: A scoping review was conducted to identify relevant studies published after 1995 by searching 5 electronic databases: PubMed, Scopus, Cumulative Index of Nursing and Allied Health Literature (CINAHL), PsycInfo, and Healthcare Administration. Eligibility was determined using the PEO (Population, Exposure, and Outcomes) method, with clearly defined populations (cancer patients), exposures (financial hardship, toxicity, or distress; travel-related burdens), and outcomes (treatment access, treatment outcomes, health-related quality of life, and survival/mortality). Study characteristics, methods, and findings were extracted and summarized. Results: Database searches yielded 6439 results, of which 3366 were unique citations. Of those, 141 were eligible for full-text review, and 98 studies at the intersection of cancer-related travel burdens and financial hardship were included. Five themes emerged as we extracted from the full texts of the included articles: 1) Cancer treatment choices, 2) Receipt of guideline-concordant care, 3) Cancer treatment outcomes, 4) Health-related quality of life, and 5) Propensity to participate in clinical trials. Conclusions: This scoping review identifies and summarizes available research at the intersection of cancer care-related travel burdens and financial hardship. This review will inform the development of future interventions aimed at reducing the negative effects of cancer-care related costs on patient outcomes and quality of life.

1 September 2022 in JCO Oncology Practice
Verified
Journal Article
Closed access
CBCaitlin B. Biddell
Caitlin B. Biddell
LSLisa P. Spees
Lisa P. Spees
VPVictoria Petermann
Victoria Petermann
DRDonald L. Rosenstein
Donald L. Rosenstein
MMMichelle Manning
Michelle Manning
SWStephanie B Wheeler
Stephanie B Wheeler
PURPOSE: Patients with cancer are at heightened risk of experiencing financial hardship. Financial navigation (FN) is an evidence-based approach for identifying and addressing patient and caregiver financial needs. In preparation for the implementation of a multisite FN intervention, we describe existing processes (ie, events and actions) and mechanisms (ie, how events work together) connecting patients to financial assistance, comparing rural and nonrural practices. METHODS: We conducted in-depth, semistructured interviews with stakeholders (ie, administrators, providers, and staff) at each of the 10 oncology care sites across a single state (five rural and five nonrural practices). We developed process maps for each site and analyzed stakeholder perspectives using thematic analysis. After reporting findings back to stakeholders, we synthesized themes and process maps across rural and nonrural sites separately. RESULTS: Eighty-three stakeholders were interviewed. We identified six core elements of existing financial assistance processes across all sites: distress screening (including financial concerns), referrals, resource connection points, and pharmaceutical, insurance, and community/foundation resources. Processes differed by rurality; however, facilitators and barriers to identifying and addressing patient financial needs were consistent. Open communication between staff, providers, patients, and caregivers was a primary facilitator. Barriers included insufficient staff resources, challenges in routinely identifying needs, inadequate preparation of patients for anticipated medical costs, and limited tracking of resource availability and eligibility. CONCLUSION: This study identified a clear need for systematic implementation of oncology FN to equitably address patient and caregiver financial hardship. Results have informed our current efforts to implement a multisite FN intervention, which involves comprehensive financial toxicity screening and systematization of intake and referrals.

7 February 2022 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
CBCaitlin B. Biddell
Caitlin B. Biddell
KKKimberly A. Kasow
Kimberly A. Kasow
MKMary K. Killela
Mary K. Killela
KPKristin M. Page
Kristin M. Page
SWStephanie B. Wheeler
Stephanie B. Wheeler
LSLisa P. Spees
Lisa P. Spees

1 April 2019 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
LSLisa P. Spees
Lisa P. Spees
PMPaul L. Martin
Paul L. Martin
JKJoanne Kurtzberg
Joanne Kurtzberg
ASAndre Stokhuyzen
Andre Stokhuyzen
LMLauren McGill
Lauren McGill
MKMatthew S. Kelly
Matthew S. Kelly
Infections and graft-versus-host disease (GVHD) have historically resulted in high mortality among children undergoing umbilical cord blood transplantation (UCBT). However, recent advances in clinical practice have likely improved outcomes of these patients. We conducted a retrospective cohort study of children (<18years of age) undergoing UCBT at Duke University between January 1, 1995 and December 31, 2014. We compared 2-year all-cause and cause-specific mortality during 3 time periods based on year of transplantation (1995 to 2001, 2002 to 2007, and 2008 to 2014). We used multivariable Cox regression to identify demographic and UCBT characteristics that were associated with all-cause mortality, transplantation-related mortality, and death from invasive aspergillosis after adjustment for time period. During the 20-year study period 824 children underwent UCBT. Two-year all-cause mortality declined from 48% in 1995 to 2001 to 30% in 2008 to 2014 (P = .0002). White race and nonmalignant UCBT indications were associated with lower mortality. Black children tended to have a higher risk of death for which GVHD (18% versus 11%; P = .06) or graft failure (9% versus 3%; P = .01) were contributory than white children. Comparing 2008 to 2014 with 1995 to 2001, more than half (59%) of the reduced mortality was attributable to a reduction in infectious mortality, with 45% specifically related to reduced mortality from invasive aspergillosis. Antifungal prophylaxis with voriconazole was associated with lower mortality from invasive aspergillosis than low-dose amphotericin B lipid complex (hazard ratio, .09; 95% confidence interval, .01 to .76). With the decline in mortality from invasive aspergillosis, adenovirus and cytomegalovirus have become the most frequentinfectious causes of death in children after UCBT. Advances in clinical practice over the past 20years improved survival of children after UCBT. Reduced mortality from infections, particularly invasive aspergillosis, accounted for the largest improvement in survival and was associated with use of voriconazole for antifungal prophylaxis.